相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。US Renal Data System 2019 Annual Data Report: Epidemiology of Kidney Disease in the United States
Rajiv Saran et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2020)
Economic burden and cost-utility analysis of three renal replacement therapies in ESRD patients from Yunnan Province, China
Huixin Wu et al.
INTERNATIONAL UROLOGY AND NEPHROLOGY (2020)
Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017
Boris Bikbov et al.
LANCET (2020)
Beneficial effects of paricalcitol on cardiac dysfunction and remodelling in a model of established heart failure
Maria Tamayo et al.
BRITISH JOURNAL OF PHARMACOLOGY (2020)
The cost-effectiveness of extended-release calcifediol versus paricalcitol for the treatment of secondary hyperparathyroidism in stage 3-4 CKD
Kamyar Kalantar-Zadeh et al.
JOURNAL OF MEDICAL ECONOMICS (2020)
The Therapeutic Effect of Active Vitamin D Supplementation in Preventing the Progression of Diabetic Nephropathy in a Diabetic Mouse Model
Nakhoul Nakhoul et al.
JOURNAL OF DIABETES RESEARCH (2020)
China Kidney Disease Network (CK-NET) 2016 Annual Data Report
Luxia Zhang et al.
Kidney International Supplements (2020)
Returning to haemodialysis after kidney allograft failure: a survival study with propensity score matching
Javier Varas et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2019)
The Importance of Adherence in the Treatment of Secondary Hyperparathyroidism
Carlo Alfieri et al.
BLOOD PURIFICATION (2019)
Long-term outcomes and management considerations after parathyroidectomy in the dialysis patient
Elijah Kakani et al.
SEMINARS IN DIALYSIS (2019)
Comparison of Paricalcitol and Calcitriol in Dialysis Patients With Secondary Hyperparathyroidism: A Meta-Analysis of Randomized Controlled Studies
Tong Zhang et al.
THERAPEUTIC APHERESIS AND DIALYSIS (2019)
Secondary Hyperparathyroidism: Pathogenesis and Latest Treatment
Masahide Mizobuchi et al.
THERAPEUTIC APHERESIS AND DIALYSIS (2019)
The effectiveness of cinacalcet: a randomized, open label study in chronic hemodialysis patients with severe secondary hyperparathyroidism
Paweena Susantitaphong et al.
RENAL FAILURE (2019)
Impact of Subtotal Parathyroidectomy on Clinical Parameters and Quality of Life in Hemodialysis Patients with Secondary Hyperparathyroidism
Mohamed Mimi Abd Elgawwad El-kholey et al.
ENDOCRINOLOGY AND METABOLISM (2019)
Paricalcitol versus placebo for reduction of proteinuria in kidney transplant recipients: a double-blind, randomized controlled trial
Manca Oblak et al.
TRANSPLANT INTERNATIONAL (2018)
Association of Dose and Frequency on the Survival of Patients on Maintenance of Hemodialysis in China: A Kaplan-Meier and Cox-Proportional Hazard Model Analysis
Yan Sun et al.
MEDICAL SCIENCE MONITOR (2018)
Perspectives in renal replacement therapy: Haemodialysis
Adrian Liew
NEPHROLOGY (2018)
Prevalence and Risk Factors for CKD: A Comparison Between the Adult Populations in China and the United States
Fang Wang et al.
KIDNEY INTERNATIONAL REPORTS (2018)
Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism A Randomized Clinical Trial
Geoffrey A. Block et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Effect of parathyroidectomy and cinacalcet on quality of life in patients with end-stage renal disease-related hyperparathyroidism: a systematic review
Willemijn Y. van der Plas et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2017)
Efficacy and safety of paricalcitol in children with stages 3 to 5 chronic kidney disease
Nicholas J. A. Webb et al.
PEDIATRIC NEPHROLOGY (2017)
Hemodialysis patients' preferences for the management of secondary hyperparathyroidism
Brett Hauber et al.
BMC NEPHROLOGY (2017)
Vitamin D in Chronic Kidney Disease and Dialysis Patients
Guillaume Jean et al.
NUTRIENTS (2017)
Impact of surgical parathyroidectomy on chronic kidney disease-mineral and bone disorder (CKD-MBD) - A systematic review and meta-analysis
Mugurel Apetrli et al.
PLOS ONE (2017)
Consensus statement on insulin therapy in chronic kidney disease
Rajesh Rajput et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2017)
Current burden of end-stage kidney disease and its future trend in China
Luxia Zhang et al.
CLINICAL NEPHROLOGY (2016)
The Economic Burden of Chronic Kidney Disease and End-Stage Renal Disease
Virginia Wang et al.
SEMINARS IN NEPHROLOGY (2016)
Forecast of the incidence, prevalence and burden of end-stage renal disease in Nanjing, China to the Year 2025
Ling Sun et al.
BMC NEPHROLOGY (2016)
Global Prevalence of Chronic Kidney Disease - A Systematic Review and Meta-Analysis
Nathan R. Hill et al.
PLOS ONE (2016)
Health Economic Evaluation of Paricalcitol(A (R)) Versus Cincalcet plus Calcitriol (Oral) in Italy
Mark Nuijten et al.
CLINICAL DRUG INVESTIGATION (2015)
Emerging drugs for secondary hyperparathyroidism
Mario Cozzolino et al.
EXPERT OPINION ON EMERGING DRUGS (2015)
Health-related quality of life of Asian patients with end-stage renal disease (ESRD) in Singapore
F. Yang et al.
QUALITY OF LIFE RESEARCH (2015)
Economic Evaluation of Cinacalcet in the United States: The EVOLVE Trial
Vasily Belozeroff et al.
VALUE IN HEALTH (2015)
Comparison of Paricalcitol With Maxacalcitol Injection in Japanese Hemodialysis Patients With Secondary Hyperparathyroidism
Tadao Akizawa et al.
THERAPEUTIC APHERESIS AND DIALYSIS (2015)
Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention
Ron T. Gansevoort et al.
LANCET (2013)
Randomized controlled trial to compare the efficacy and safety of oral paricalcitol with oral calcitriol in dialysis patients with secondary hyperparathyroidism
Loke Meng Ong et al.
NEPHROLOGY (2013)
Vitamin D supplementation and mortality risk in chronic kidney disease: a meta-analysis of 20 observational studies
Zhenfeng Zheng et al.
BMC NEPHROLOGY (2013)
Comparative cost analysis of management of secondary hyperparathyroidism with paricalcitol or cinacalcet with low-dose vitamin D in hemodialysis patients
Amit Sharma et al.
JOURNAL OF MEDICAL ECONOMICS (2013)
Cost-Effectiveness of Cinacalcet Hydrochloride for Hemodialysis Patients With Severe Secondary Hyperparathyroidism in Japan
Hirotaka Komaba et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2012)
Prevalence of chronic kidney disease in China: a cross-sectional survey
Luxia Zhang et al.
LANCET (2012)
Efficacy and Tolerability of Intravenous Paricalcitol in Calcitriol-Resistant Hemodialysis Patients with Secondary Hyperparathyroidism: 12-Month Prospective Study
Halil Zeki Tonbul et al.
RENAL FAILURE (2012)
Effectiveness of cinacalcet in patients with recurrent/persistent secondary hyperparathyroidism following parathyroidectomy: results of the ECHO study
Emanuel Zitt et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2011)
Cost Effectiveness of Paricalcitol versus a Non-Selective Vitamin D Receptor Activator for Secondary Hyperparathyroidism in the UK A Chronic Kidney Disease Markov Model
Mark Nuijten et al.
CLINICAL DRUG INVESTIGATION (2010)
Chronic kidney disease Markov model comparing paricalcitol to calcitriol for secondary hyperparathyroidism: a US perspective
Mark Nuijten et al.
CURRENT MEDICAL RESEARCH AND OPINION (2009)
Parathyroidectomy versus cinacalcet hydrochloride-based medical therapy in the management of hyperparathyroidism in ESRD: A cost utility analysis
Rajeev Narayan et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2007)
Intravenous paricalcitol for treatment of secondary hyperparathyroidism in children on hemodialysis
Larry A. Greenbaum et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2007)
Health-economic comparison of paricalcitol, calcitriol and alfacalcidol for the treatment of secondary hyperparathyroidism during haemodialysis
Hubertus Rosery et al.
CLINICAL DRUG INVESTIGATION (2006)
Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitriol-treated patients in real-world clinical settings
DG Dobrez et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2004)
Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy
M Teng et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism
SM Sprague et al.
KIDNEY INTERNATIONAL (2003)
Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism
F Llach et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2001)
分享论文
